TD Private Client Wealth LLC Has $508,000 Position in GSK plc (NYSE:GSK)

TD Private Client Wealth LLC boosted its holdings in GSK plc (NYSE:GSK) by 36.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,422 shares of the pharmaceutical company’s stock after buying an additional 3,346 shares during the quarter. TD Private Client Wealth LLC’s holdings in GSK were worth $508,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. Eastern Bank acquired a new position in shares of GSK during the third quarter worth $26,000. Sunbelt Securities Inc. increased its stake in GSK by 73.8% in the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after purchasing an additional 302 shares in the last quarter. Concord Wealth Partners increased its position in GSK by 231.8% in the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock valued at $32,000 after buying an additional 547 shares in the last quarter. Ashton Thomas Private Wealth LLC acquired a new position in shares of GSK during the second quarter worth approximately $37,000. Finally, Fortitude Family Office LLC bought a new position in shares of GSK in the third quarter valued at $42,000. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Stock Performance

Shares of NYSE:GSK opened at $33.95 on Friday. The firm’s 50-day moving average is $36.18 and its 200 day moving average is $39.25. The company has a market capitalization of $70.36 billion, a price-to-earnings ratio of 22.05, a PEG ratio of 1.54 and a beta of 0.64. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. GSK plc has a 12 month low of $32.83 and a 12 month high of $45.92.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 9th. Stockholders of record on Friday, November 15th will be given a $0.3928 dividend. This represents a $1.57 annualized dividend and a dividend yield of 4.63%. The ex-dividend date is Friday, November 15th. This is a boost from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio is presently 99.35%.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on GSK shares. Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and reduced their price target for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research report on Thursday. Deutsche Bank Aktiengesellschaft cut GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, Barclays raised GSK to a “hold” rating in a research note on Tuesday, August 27th. Seven investment analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company. According to data from MarketBeat.com, GSK has a consensus rating of “Moderate Buy” and an average target price of $43.25.

Insider Buying and Selling at GSK

In other GSK news, major shareholder Plc Gsk purchased 2,791,930 shares of the stock in a transaction on Friday, September 27th. The shares were bought at an average price of $8.00 per share, for a total transaction of $22,335,440.00. Following the completion of the transaction, the insider now owns 16,775,691 shares of the company’s stock, valued at $134,205,528. This trade represents a 19.97 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders own 10.00% of the company’s stock.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.